AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28255849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (CdA) as a single agent or in combination with interferon (IFN) β‐1a
Number of subjects: 173
Study 28255849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (CdA)
Number of subjects: 173
Study 28255849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (CdA) with coadministration of interferon (IFN) β‐1a
Number of subjects: 173
Study 26096249 — intervention group
Group type: EXPERIMENTAL
Intervention: OneShape Endodontic File no.: 25
Number of subjects: 50
Study 26096249 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Endodontic File no.: 25
Number of subjects: 50
Study 26096249 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Endodontic File no.: 25
Number of subjects: 50
Study 23432142 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 323
Study 23432142 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg
Number of subjects: 323
Study 23432142 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 323
Study 23432142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 21333265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Thermographer measurements after 10 seconds of eye opening
Number of subjects: 60
Study 19167081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine eyedrops once nightly for 2 years
Number of subjects: 400
Study 19167081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) eyedrops once nightly for 2 years
Number of subjects: 400
Study 19167081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine eyedrops
Number of subjects: 400
Study 19167081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) eyedrops
Number of subjects: 400
Study 16913434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT at 1,000 micromol/L
Number of subjects: 12
Study 16913434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT at 0.1 micromol/L
Number of subjects: 12
Study 16913434 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 12
Study 12773363 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sessions provided to couples together (n = 81)
Number of subjects: 217
Study 12773363 — intervention group
Group type: EXPERIMENTAL
Intervention: The same intervention provided to the woman alone (n = 73)
Number of subjects: 217
Study 12773363 — intervention group
Group type: COMPARATOR
Intervention: 1-session control condition provided to the woman alone (n = 63)
Number of subjects: 217
Study 11132390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae (0.1 mL)
Number of subjects: 204
Study 11132390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 mL tetanus toxoid)
Number of subjects: 204
Study 9061219 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisolone/day for 2 weeks
Number of subjects: 30
Study 9061219 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral prednisolone/day for 2 weeks
Number of subjects: 30
Study 9061219 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg inhaled budesonide/day for 2 weeks
Number of subjects: 30
Study 8460064 — intervention group
Group type: EXPERIMENTAL
Intervention: End inspiratory occlusion times of 90 to 275 ms
Number of subjects: 36
Study 8460064 — intervention group
Group type: EXPERIMENTAL
Intervention: End inspiratory occlusion times longer than 275 ms
Number of subjects: 36
Study 8460064 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusions between 300 and 450 ms
Number of subjects: 36
Study 8460064 — intervention group
Group type: EXPERIMENTAL
Intervention: Age range for applying this method
Number of subjects: 36
Study 3535621 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (Rinexin) 50 mg twice daily
Number of subjects: 43
Study 3535621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30218844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor
Number of subjects: 2009
Study 27018532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP + BAI
Number of subjects: 97
Study 27018532 — intervention group
Group type: COMPARATOR
Intervention: SBP
Number of subjects: 97
Study 25467378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral vapour ablation in addition to standard medical management
Number of subjects: 69
Study 25467378 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management alone
Number of subjects: 69
Study 25467378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 69
Study 21842236 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Hand technique
Number of subjects: 20
Study 21842236 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Free Hand technique
Number of subjects: 20
Study 20438514 — intervention group
Group type: COMPARATOR
Intervention: Conventional (potentially contaminated) dialysate
Number of subjects: 48
Study 20438514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate
Number of subjects: 48
Study 18640108 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate
Number of subjects: 5
Study 18640108 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg propofol
Number of subjects: 5
Study 18640108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 5
Study 17264833 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 17264833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 12665540 — intervention group
Group type: EXPERIMENTAL
Intervention: 110% CP
Number of subjects: 6
Study 12665540 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% CP
Number of subjects: 6
Study 12665540 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% theta(L)
Number of subjects: 6
Study 11013280 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days
Number of subjects: 414
Study 11013280 — intervention group
Group type: COMPARATOR
Intervention: High-dose cisplatin (100 mg/m(2))
Number of subjects: 414
Study 8780837 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (1 mg/kg daily for 4 weeks)
Number of subjects: 23
Study 8780837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1622413 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered after an overnight fast
Number of subjects: 12
Study 1622413 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered within 10 minutes of consuming a high fat‐content breakfast
Number of subjects: 12
Study 6421561 — intervention group
Group type: EXPERIMENTAL
Intervention: New glibenclamide preparation (Euglucon 5, HB 419)
Number of subjects: 12
Study 6421561 — intervention group
Group type: COMPARATOR
Intervention: Conventional glibenclamide preparation (Euglucon N, HB 420)
Number of subjects: 12
Study 31929499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel-like fistulectomy plus draining seton combined with incision of internal opening of anal fistula (TFSIA)
Number of subjects: 80
Study 31929499 — intervention group
Group type: COMPARATOR
Intervention: Cutting seton (Control)
Number of subjects: 80
Study 29760159 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+ (methotrexate therapy with hydroxychloroquine added if no remission)
Number of subjects: 108
Study 29760159 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+
Number of subjects: 108
Study 29760159 — intervention group
Group type: COMPARATOR
Intervention: Prediction model
Number of subjects: 108
Study 27896461 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block using 20 mL of 0.375% ropivacaine
Number of subjects: 64
Study 27896461 — intervention group
Group type: COMPARATOR
Intervention: Placebo group using 20 mL of 0.9% normal saline infusion
Number of subjects: 64
Study 27896461 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 64
Study 24532502 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of dual antiplatelet therapy (DAPT) due to unexpected requests for non-cardiac surgery or invasive procedures
Number of subjects: 2117
Study 24532502 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiac surgery or procedure performed after requests
Number of subjects: 2117
Study 24532502 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent implantation with 3-month DAPT
Number of subjects: 2117
Study 24532502 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of request for surgery or procedure
Number of subjects: 2117
Study 24532502 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes related to DAPT discontinuation
Number of subjects: 2117
Study 23731986 — intervention group
Group type: EXPERIMENTAL
Intervention: Irish set dancing classes once per week plus a weekly home program for 6 months
Number of subjects: 24
Study 23731986 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy exercises
Number of subjects: 24
Study 19895590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for Mini Rhinoconjunctivitis Quality of Life Questionnaire)
Number of subjects: 204
Study 19895590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for peak nasal inspiratory flow)
Number of subjects: 204
Study 19895590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for total nasal symptoms score)
Number of subjects: 204
Study 19895590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Nasal NO measurement)
Number of subjects: 204
Study 18801576 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 72
Study 18801576 — intervention group
Group type: COMPARATOR
Intervention: Combined phacotrabeculectomy with adjunctive mitomycin C
Number of subjects: 72
Study 15986752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal rotation flaps
Number of subjects: 74
Study 15986752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal V‐Y flaps
Number of subjects: 74
Study 15986752 — intervention group
Group type: EXPERIMENTAL
Intervention: Transposition flaps
Number of subjects: 74
Study 15986752 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention with postoperative care
Number of subjects: 74
Study 15986752 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotic therapy and late suture removal
Number of subjects: 74
Study 12460865 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (three 5-minute cycles of ischemia of the contralateral limb)
Number of subjects: 0
Study 12460865 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb ischemia (20 minutes of upper limb ischemia)
Number of subjects: 0
Study 12460865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remote preconditioning)
Number of subjects: 0
Study 10874387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fieller's confidence interval method
Number of subjects: 0
Study 10874387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap confidence interval methods
Number of subjects: 0
Study 7482373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 7482373 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (implied control)
Number of subjects: 0
Study 1753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus saprophyticus infection
Number of subjects: 270
Study 1753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic S. saprophyticus infection
Number of subjects: 270
Study 1753113 — intervention group
Group type: EXPERIMENTAL
Intervention: S. saprophyticus as the cause of urinary tract infections
Number of subjects: 270
Study 1753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with nephrolithiasis
Number of subjects: 270
Study 1753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-induced infections
Number of subjects: 270
Study 7125306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 16
Study 7125306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 5.0 mg
Number of subjects: 16
Study 7125306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 7.5 mg
Number of subjects: 16
Study 7125306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 24 mg
Number of subjects: 16
Study 7125306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31775696 — intervention group
Group type: EXPERIMENTAL
Intervention: GReat-Child Trial™ intervention
Number of subjects: 63
Study 31775696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 29246256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycine (0.5 g/kg/day, dissolved in any liquid)
Number of subjects: 13
Study 29246256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glass sugar)
Number of subjects: 13
Study 25648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet (T-group)
Number of subjects: 64
Study 25648580 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (NT-group)
Number of subjects: 64
Study 24825180 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term proton pump inhibitor therapy (>1 year)
Number of subjects: 0
Study 22932247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal septal cartilage combined with ePTFE (group A)
Number of subjects: 118
Study 22932247 — intervention group
Group type: COMPARATOR
Intervention: Autologous auricular cartilage grafts (group B)
Number of subjects: 118
Study 19576351 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSID (Computerized Angioplasty Pressure Sensor and Inflator Device)
Number of subjects: 310
Study 19576351 — intervention group
Group type: COMPARATOR
Intervention: Standard manual percutaneous coronary intervention (Control)
Number of subjects: 310
Study 17538639 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG) 50 mg/day for 3 months
Number of subjects: 38
Study 17538639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17538639 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG)
Number of subjects: 38
Study 15779317 — intervention group
Group type: COMPARATOR
Intervention: Excite (EX, Ivoclar‐Vivadent) on enamel
Number of subjects: 40
Study 15779317 — intervention group
Group type: COMPARATOR
Intervention: Excite (EX, Ivoclar‐Vivadent) on dentin
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE (AS, Ivoclar‐Vivadent) on dentin
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno CF II (X, Sanking Kogyo) on dentin
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop (AP, 3M ESPE) on dentin
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE (AS, Ivoclar‐Vivadent) on enamel
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno CF II (X, Sanking Kogyo) on enamel
Number of subjects: 40
Study 15779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop (AP, 3M ESPE) on enamel
Number of subjects: 40
Study 11782694 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene), 200 mg three times daily for 6 months
Number of subjects: 235
Study 11782694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 11195304 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention shifting turned on
Number of subjects: 0
Study 11195304 — intervention group
Group type: COMPARATOR
Intervention: Attention shifting turned off
Number of subjects: 0
Study 9513821 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for gastro-oesophageal reflux
Number of subjects: 50
Study 9513821 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for non-ulcer dyspepsia with Helicobacter pylori eradication
Number of subjects: 50
Study 9513821 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for duodenal ulceration
Number of subjects: 50
Study 9513821 — intervention group
Group type: COMPARATOR
Intervention: Prokinetic agent for non-ulcer dyspepsia
Number of subjects: 50
Study 9513821 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study 8443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine (200 mg orally four times a day)
Number of subjects: 172
Study 8443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylmethionine sulfonium chloride (MMSC) (500 mg orally four times a day)
Number of subjects: 172
Study 8443719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 172
Study 3821139 — intervention group
Group type: EXPERIMENTAL
Intervention: Calea zacatechichi extracts (low doses)
Number of subjects: 0
Study 3821139 — intervention group
Group type: EXPERIMENTAL
Intervention: Calea zacatechichi extracts
Number of subjects: 0
Study 3821139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3821139 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31355870 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the disease-affected meridian (DAM)
Number of subjects: 404
Study 31355870 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture on the nonaffected meridian (NAM)
Number of subjects: 404
Study 31355870 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 404
Study 31355870 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (wait list [WL] group)
Number of subjects: 404
Study 30241722 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg per day for 21 days)
Number of subjects: 236
Study 30241722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (22.5 mg/kg, twice daily for 21 days)
Number of subjects: 236
Study 30241722 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 236
Study 30241722 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 236
Study 27048694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid 1g 10 min bolus followed by 1g 8h infusion
Number of subjects: 2000
Study 27048694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 24754183 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing kidney, activating blood circulation and ovarian stimulation compound recipe (treatment group)
Number of subjects: 60
Study 24754183 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (control group)
Number of subjects: 60
Study 22187510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 17120
Study 22187510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17120
Study 20388052 — intervention group
Group type: EXPERIMENTAL
Intervention: IAsp CSII
Number of subjects: 61
Study 20388052 — intervention group
Group type: COMPARATOR
Intervention: IAsp MDI
Number of subjects: 61
Study 20388052 — intervention group
Group type: COMPARATOR
Intervention: HI MDI
Number of subjects: 61
Study 18373490 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily (q.d.)
Number of subjects: 276
Study 18373490 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily (b.i.d.)
Number of subjects: 276
Study 18373490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 18373490 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg with a 200 mg redose (p.r.n.) on day 1
Number of subjects: 276
Study 15836932 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive electrogoniometer measurements
Number of subjects: 9
Study 12431168 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (pamphlet with written information and illustrations)
Number of subjects: 121
Study 12431168 — intervention group
Group type: COMPARATOR
Intervention: Control (verbal checklist of risks only)
Number of subjects: 121
Study 9886446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 110
Study 9886446 — intervention group
Group type: COMPARATOR
Intervention: Other secondary insults (not specified)
Number of subjects: 110
Study 7792793 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (K‐Can) 50 mg/day for 4 weeks
Number of subjects: 50
Study 7792793 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg for 4 weeks
Number of subjects: 50
Study 7792793 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 25 mg for 4 weeks
Number of subjects: 50
Study 7792793 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks before each treatment
Number of subjects: 50
Study 1673723 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (H1 receptor blocker)
Number of subjects: 60
Study 1673723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31086126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus administered via nasogastric tube on Day 1
Number of subjects: 10
Study 31086126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus administered via nasogastric tube on Day 3
Number of subjects: 10
Study 27858183 — intervention group
Group type: EXPERIMENTAL
Intervention: THP (25 mg/m2 × 11)
Number of subjects: 276
Study 27858183 — intervention group
Group type: COMPARATOR
Intervention: DNR (30 mg/m2 × 11)
Number of subjects: 276
Study 26109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories (200000 IU every 8 hours for the first 3 units, then every 12 hours until 8 administrations completed)
Number of subjects: 421
Study 26109819 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate suppositories (25 mg every 8 hours up to a maximum of 24 administrations)
Number of subjects: 421